Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Catalent, Inc.

OneDrug is a pioneering medical technology startup focused on advancing precision medicine for better patient outcomes. It empowers healthcare providers with smart point-of-care technologies to personalize patient treatment.

OneDrug

Applikon Bio provides bioprocess equipment and automation solutions for biotechnology research and production

Applikon Bio

Pharma Manufacturing provides information and resources related to the pharmaceutical manufacturing sector, including industry news, articles, and events.

Pharma Manufacturing

Catalent provides contract development and manufacturing services (CDMO) for the pharmaceutical and biotech industries, offering solutions for drug development, delivery, and supply chain management.

Metric
Company Name	Catalent, Inc.	OneDrug	Applikon Bio	Pharma Manufacturing
Symbol	CTLT
MSH ID	COM:CATALENT	CO:ONEDRUG	COM:APPLIKONBIO	COM:PHARMAMANUFACTURING
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Commercial & Professional Services
Industry	Drug Manufacturers - Specialty & Generic	Medical Devices	Biotechnology Equipment	Pharmaceuticals
Country	US	US	NL	US
Stage
Employee Count	18K
Website	catalent.com	onedrug.co	applikonbio.com	pharmamanufacturing.com
LinkedIn			applikon-biotechnology
Founders

Metric
Market Cap	10.39B
Enterprise Value
Monthly Web Traffic	215.31K	6.54K
Web Traffic Growth	0.22	-0.82
Valuation
Raised Capital

Metric
Revenue	4.38B
Revenue (LTM)
Revenue (NTM)
Gross Profit	953M
EBITDA	634M
Operating Income	145M
Net Income	-1.04B
EPS	-5.76
Diluted EPS	-5.76
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.22
Operating Profit Margin	-0.14
EBITDA Margin	0.14
Net Profit Margin	-0.23
Return on Equity	-0.27
Return on Assets	-0.10
Return on Capital Employed	-0.07

COM:CATALENT

Catalent

Last Close

59.66

22/11 21:00

Market Cap

10.39B

Beta: -

Volume Today

4.87M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-11.39
P/B Ratio	2.76
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.61
EV Multiple	88.01

Metric
Days Sales Outstanding	71.17
Days Payables Outstanding	41.18
Days Inventory Outstanding	84.59
Operating Cycle	208.07
Cash Conversion Cycle	166.77
Asset Turnover	0.45

Metric
Operating Cash Flow	268M
Free Cash Flow	268M
Cash Flow to Debt	0.06
Operating Cash Flow/Sales	0.06
Free Cash Flow Yield	-0.02

Metric
Cash & Equivalents	289M
Accounts Receivable
Inventory	574M
Goodwill
Debt to Capitalization	0.58
Debt to Assets	0.49
Current Ratio	1.71
Quick Ratio	1.96

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01
R&D to Revenue
SG&A to Revenue